Everolimus is a rapamycin inhibitor and the clinical immunosuppressant used after organ transplantation.[76,77] Everolimus reduces the donor-specific HLA antibodies and endothelial cell injury in heart transplants.[78] Gemcitabine promotes tumor cell-derived inflammatory responses, including decreased IFN-γ-producing CD4 and CD8 T cells, and therefore resulting in immunosuppression in mouse model.[79] Also, the combination of gemcitabine with rosiglitazone decreased the immunosuppression in immunocompetent animals,[80] as it enhances circulating CD8+ T cells and limiting Treg cells. This evidence concerns the gene CD8A and neoplasm.